Susan T. Hager
Vice President, Investor Relations and Corporate Communications

Susan T. Hager joined Targanta Therapeutics in May 2008 as Vice President, Investor Relations and Corporate Communications. She has more than a decade of corporate marketing communications, investor relations and public relations experience with biotechnology, pharmaceutical, and medical device companies. Most recently, Ms. Hager was at Coley Pharmaceutical Group, where she served as Vice President of Investor Relations, Corporate Communications and Corporate Development from 2006-2008. Prior to that, Ms. Hager was head of Corporate and Investor Relations for OXiGENE, Inc. Ms. Hager worked in various global marketing communications roles for Bayer Healthcare LLC where she contributed to several successful product launches including the RapidLab� 1200 blood gas analyzer. From 1998-2003, she served in various roles of increasing responsibility for SHIFT Communications, a technology and healthcare strategic communications agency, and ultimately served as the firm's Vice President, Health Services Communications. She is a member of the National Investor Relations Institute (NIRI), as well as a steering committee member of NIRI's BioPharma Roundtable. Ms. Hager received a BS in Biology and an MBA from Northeastern University in Boston, MA.